Drug Trial Radar · NCT06434597
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 17, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.
Conditions
- Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Interventions
SPH5030Drug
SPH5030:Oral, QD, 600mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Approximately 2 years
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital,Capital Medical University
Beijing, China · Recruiting
Chinese PLA General hospital
Beijing, China · Recruiting
Peking Union Medical College Hospital
Beijing, China · Recruiting
The Second Affiliatedf Hospital of AFMU
Beijing, China · Recruiting
XiangYa Hospital CentralSouth University
Changsha, China · Recruiting
Changzhi People's Hospital
Changzhi, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
General Hospital of Fuzhou
Fuzhou, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, China · Recruiting
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine
Hangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, China · Recruiting
Hengshui People's Hospital
Hengshui, China · Recruiting
Yunnan Cancer Hospital
Kunming, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Shanghai General Hospital
Shanghai, China · Recruiting
The Third Affiliated Hospital of Air Force Medical University
Shanghai, China · Recruiting
Zhongshan Hospital
Shanghai, China · Recruiting
Shantou University Medical College Cancer Hospital
Shantou, China · Recruiting
Liaoning Cancer Hospital
Shenyang, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, China · Recruiting
Tianjin Medical University Cancer institute & Hospital
Tianjin, China · Recruiting
Hubei Cancer Hospital
Wuhan, China · Recruiting
Affiliated Hospital of Jiangnan University
Wuxi, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, China · Recruiting
Xiangyang Central Hospital
Xiangyang, China · Recruiting
Yantai Yuhuangding Hospital
Yantai, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.